Compass Pathways Q3 Earnings Call Highlights

Key Points

• Compass Pathways expects to complete its rolling New Drug Application for COMP360 within two weeks, supported by two statistically significant Phase III trials and a positive Phase IIb study. A National Priority Voucher could enable an FDA review target of 30–60 days, with a potential U.S. launch in the first half of 2027.
• The company is preparing its commercial infrastructure, including field-force hiring and partnerships with more than 8,500 interventional psychiatry centers. COMP360 is expected to use specialty-pharmacy and buy-and-bill distribution models, subject to federal and state rescheduling and a final REMS.
• Compass reported $444 million in cash as of Sept. 30 and expects funding to support operations through a potential launch and into 2028. Its pipeline includes an actively enrolling late-stage PTSD trial, while the company cites treatment-resistant depression’s estimated 4 million U.S. patients as a significant market opportunity.

Compass Pathways NASDAQ: CMPS said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within two weeks, as the company prepares for a potential U.S. launch in the first half of 2027.

Chief Executive Officer Kabir Nath said the company’s submission includes two statistically significant Phase III studies and a positive Phase IIb study that collectively enrolled more than 1,000 patients. Compass has received a National Priority Voucher, which Nath said establishes an FDA review target of one to two months and could support a rapid approval timeline.

“We are prepared for the potential that we might actually get a complete approval within that 30-60-day timeline,” Nath said during the company’s third-quarter conference call, while noting that historical precedents have varied.

Regulatory Process and Rescheduling

Compass said its interactions with the FDA have remained productive during the rolling submission process. Nath said the company believes its application will meet the agency’s standards for scientific rigor, but did not provide detailed commentary on the prospective product label or final Risk Evaluation and Mitigation Strategy, or REMS.

The company also discussed federal drug rescheduling as a separate consideration from FDA review. Chief Commercial Officer Lori Englebert said an executive order related to Drug Enforcement Administration rescheduling is intended to encourage a faster process than the DEA’s 90-day statutory timeline. However, she said Compass has limited visibility into the ultimate timing.

Englebert added that state-level rescheduling must also occur before COMP360 can be prescribed and administered. She said more than 93% of the U.S. population lives in states that have indicated they intend to reschedule within 30 days of federal DEA action.

Compass expects its prospective REMS to use the existing SPRAVATO REMS as a template, based on FDA direction, according to Nath. Chief Patient Officer Dr. Steve Levine said the company anticipates healthcare-provider training content within the REMS would require about one to two hours to complete. He said the company expects final monitoring requirements to be no more stringent than those used in its clinical trials, which involved one primary monitor supplemented by closed-circuit video monitoring and two healthcare providers overall.

Commercial Launch Preparation

Compass is building commercial infrastructure ahead of a potential launch. Englebert said all planned non-field-based commercial roles have been filled and the company is now recruiting its field organization. The company’s commercial leadership team has collectively led more than 65 product launches at companies including Johnson & Johnson, Gilead, Otsuka, Axsome and Intra-Cellular, she said.

The company plans to initially use existing interventional psychiatry treatment centers, which provide in-office treatments requiring extended monitoring. Englebert said there are more than 8,500 such centers in the U.S., a network that has expanded since the launch of SPRAVATO seven years ago.

Compass plans to make COMP360 available through both specialty pharmacy and buy-and-bill models, with the drug reimbursed through the pharmacy benefit. Englebert said buy-and-bill adoption for SPRAVATO is estimated at roughly 30% to 40% of volume and could serve as a proxy for how the model may develop for COMP360 over time.

Levine said the company expects the transition of CPT Category III codes to Category I codes to take approximately 12 to 18 months. In the interim, Compass plans to support treatment sites with coding guidance and offer patient-support programs intended to reduce affordability barriers.

• Compass plans to report launch metrics in 2027, including REMS certifications, prescriptions, prescribers and payer access.
• The company said it will provide site support around reimbursement, coding, patient access and treatment logistics.
• Englebert said Compass expects its “white glove” launch approach to include support for clinics navigating monitoring, REMS and reimbursement requirements.

Market Opportunity and Positioning

Nath said approximately 4 million people in the U.S. have treatment-resistant depression, while fewer than 3% are treated with the only currently marketed product approved for that indication, SPRAVATO. Compass argues that COMP360’s potential rapid onset and less frequent dosing could differentiate it from existing options.

Levine said patients in Compass’ clinical studies had generally been in their current depressive episode for three to four years. While the company has not yet analyzed efficacy by the number of treatments that had failed individual patients, he said it would be reasonable to expect patients with less refractory disease could be more likely to benefit. Compass’ studies enrolled patients after at least two prior treatment failures, meaning the company does not have data for patients with zero to two failures, Englebert said.

In market research cited by Englebert, approximately 90% of surveyed interventional psychiatrists said they would prescribe COMP360 within its first year of availability. The company also cited patient and caregiver surveys describing the burden associated with treatment-resistant depression, although it did not provide details on the size or methodology of those surveys during the call.

Pipeline, Intellectual Property and Financial Position

Compass said its registrational late-stage PTSD trial is actively enrolling. Nath said PTSD affects more than 13 million U.S. adults and represents the company’s next planned label-expansion opportunity. He also identified substance use disorders, bipolar II disorder and obsessive-compulsive disorder as areas of potential future interest.

The company said it remains confident in its polymorph patent portfolio for COMP360. Nath said the relevant patent family extends to 2038 before any potential patent-term restoration and has previously withstood challenges and appeals.

Compass reported $444 million in cash as of Sept. 30 and said it expects its balance sheet to fund operations through a potential launch and into 2028. Nath said the company’s near-term priority remains maximizing a 2027 launch for COMP360 in treatment-resistant depression.

About Compass Pathways (NASDAQ:CMPS)

Compass Pathways plc is a biotechnology company developing novel treatments for mental health conditions. The company's lead investigational product is COMP360, a proprietary formulation of synthetic psilocybin administered with psychological support in a controlled clinical setting.

Compass Pathways has focused primarily on treatment-resistant depression, a condition in which patients do not respond adequately to existing therapies. Its research programs have included mid- and late-stage clinical trials designed to evaluate the safety and effectiveness of COMP360, as well as studies exploring its potential use in other mental health disorders.

Founded in 2016 and headquartered in London, Compass Pathways conducts research and clinical development activities across the United States, the United Kingdom and other international markets.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.